Myopia control, newly authorized
Glasses that are meant to slow myopia, not just correct it
Not because they make the board look sharper today — because they are indicated to slow how fast nearsightedness gets worse. Here is what the September 2025 authorization actually says, what the two-year trial numbers mean, and what they do not.
Buddy's quick answer
Stellest is the first eyeglass lens the FDA has authorized to slow myopia progression in children who start treatment at ages 6 to 12. In the US pivotal trial, children in Stellest progressed about 71% less in prescription (cycloplegic spherical equivalent) and about 53% less in axial eye growth over 24 months versus single-vision glasses. They are not a cure, not for every prescription, and not a substitute for exams. Ask a paediatric eye doctor whether your child fits the labeled range, and whether spectacles, contacts, drops or outdoor time is the better next step.
The short version
What Stellest actually is
Everyday single-vision kids' lenses correct blur. Stellest is still a spectacle lens — it sits in a normal frame — but the design is different.
Per the FDA: there is a clear central zone about 9 mm across for distance vision, surrounded by rings of tiny raised “lenslets.” Those peripheral lenslets create peripheral light defocus, which is the mechanism researchers believe can slow how quickly the eye elongates.
Parents will hear brand language like HALT (Highly Aspherical Lenslet Target). You do not need the acronym. What matters clinically is: clear centre for seeing, structured periphery intended to slow progression, worn as glasses for most of the waking day.
What the FDA authorized
Date, pathway, and who it is for
On 25 September 2025 the FDA authorized marketing of Essilor Stellest eyeglass lenses through the De Novo pathway — a new device type — after a Breakthrough Device designation in 2021. The manufacturer is Essilor of America Inc.
The labeled indication, in summary: correction of myopia with or without astigmatism, and slowing myopia progression, in children with non-diseased eyes who at initiation are 6 to 12 years old, with spherical equivalent roughly −0.75 D to −4.50 D and astigmatism up to about 1.50 D. The FDA's press announcement states the age range; the refractive limits come from secondary summaries of the labeling, so confirm the exact range with the prescribing clinician and the current instructions for use.
The FDA's public point was practical. MiSight-style myopia-control contacts were already authorized for roughly ages 8 to 12. Stellest can cover 6- and 7-year-olds, and children who cannot or will not wear contacts — with a lower infection-risk profile than contact lenses.
The trial numbers
What “71%” and “53%” actually refer to
The FDA reviewed two-year data from a US randomized controlled study (FIN-3101) comparing Stellest to single-vision control lenses. Over 24 months, myopia progression (cycloplegic spherical equivalent) was about −0.25 D with Stellest versus −0.90 D with single-vision controls — a relative reduction of roughly 71%. Axial length increase was about 0.21 mm versus 0.45 mm — a relative reduction of roughly 53%.
Independent write-ups of the same trial note roughly 175 children enrolled across nine US sites, with most completing 24 months of follow-up. Some wearers reported visual symptoms such as blur or halos. No serious adverse events were reported in the clinical study, according to the FDA.
How it fits the menu
Stellest vs contacts, Ortho-K, atropine and outdoor time
Myopia control is a category, not one product. Glasses sit alongside contacts, overnight lenses, drops and behaviour — and none of them replace a dilated paediatric exam, or follow-up that tracks axial length rather than only the prescription on the paper.
Myopia-control spectacles (Stellest)
The glasses pathway. FDA-authorized for initiation at ages 6 to 12 in the labeled prescription band. No contact-lens infection risk. The child still has to wear them for most of the waking day for the control effect to matter.
Soft myopia-control contacts (e.g. MiSight)
FDA-authorized contact option, historically for older starters at about 8 to 12. Daily wear and hygiene matter. A strong choice for some families; a non-starter for others.
Ortho-K, atropine, and outdoor time
Ortho-K (overnight rigid lenses) can slow axial growth in studies — around the 50% range in AAO assessments — but carries microbial keratitis risk and needs strict hygiene. Low-dose atropine is a pharmaceutical option, clinician-led on dosing and monitoring. Outdoor time remains the strongest free lever associated with lower onset risk; it does not replace optical or medical treatment once progression is under way.
What parents assume
Limits and expectations, side by side
| What parents assume | What the evidence and label show | |
|---|---|---|
| What Stellest does | Cures or freezes myopia | Slows progression relative to single-vision glasses. It does not reverse elongation that has already happened |
| Who it is for | Any nearsighted child | On-label initiation ages 6 to 12, roughly −0.75 D to −4.50 D, astigmatism up to about 1.50 D |
| The 71% figure | Your child worsens only 29% | An average relative reduction versus control over 24 months in FIN-3101 — not an individual guarantee |
| Glasses vs contacts | Contacts are always “stronger” | Different modalities, age bands and risk profiles. Stellest fills a glasses gap, including ages 6 and 7 |
| Wear time | Occasional wear is enough | Instructions in this category typically emphasise long daily wear, most days of the week. Confirm the current instructions |
| After stopping | Progress stays slowed forever | Rebound after cessation is still being studied. Essilor has discussed postmarket follow-up on that question |
Cost and insurance coverage are unsettled for many families. Plan for that conversation up front, alongside spare glasses, sports eyewear and a school backup plan. Those needs do not disappear because the optics are clinical.
What to ask
The appointment script that actually helps
Look at the label with the doctor
Ask whether your child fits the Stellest age and prescription range, or whether another option is a better fit. Off-label curiosity is fine; off-label assumption from a blog post is not.
Ask how they will measure success
“Are we tracking axial length, or only refraction?” is the single most useful sentence in this conversation. The prescription alone can miss the elongation story.
Get the wear-time number in writing
How many hours a day, how many days a week, for this to be worth doing — and what side effects, such as halos or blur, to expect in the first weeks.
Plan the exit as carefully as the start
If you stop, what is the rebound plan? What is the total cost for lenses plus follow-ups, and what might insurance cover?
Parent questions
The stuff you actually want to know
Are Stellest lenses just thicker progressive glasses?
No. They are single-vision correction in the centre with a peripheral lenslet array designed for myopia control — not a standard adult progressive. The clear central zone is about 9 mm across; the control effect sits in the surrounding lenslets and in wear time.
Can my 5-year-old use them?
The US authorization describes initiation at ages 6 to 12. Younger children need an individualised clinician plan; do not assume off-label use from an article.
If the trial showed about 71% less progression, will my child only get 29% worse?
Not individually. That figure is an average relative reduction versus control lenses in a specific trial population over two years. Some children progress more, some less.
Do we still need polycarbonate or Trivex for recess?
Impact resistance is a separate decision from myopia-control optics. Ask which materials are available in the control design your doctor recommends, and keep sports eyewear rules in mind for ball sports.
Is this better than MiSight?
Different modality, different age bands, different risk profiles. Better depends on age, hygiene, lifestyle, and what the child will actually wear for most of the day. Stellest's practical edge for some families is simply that it is glasses, including for 6- and 7-year-olds who are not contact candidates.
Will EyeBuddy stock Stellest?
No. Treat this as clinical lens technology dispensed through eye-care channels that can order the lens. Frame choice still matters for fit and compliance, but the control effect is in the lens design and the wear time, not the brand on the temple tips.
Keep exploring
Helpful next reads
If the bigger question is why the prescription keeps climbing, start with why is my child's eyesight getting worse — childhood myopia in plain language. School vision screening vs a comprehensive eye exam covers the gap between a pass/fail letter and a real dilated workup. Lazy eye is another condition children rarely report themselves. And if the practical problem is breakage and lost school days, does my child need a backup pair? and why regular glasses aren't protection are the next stops.
Where this comes from
Sources
FDA press announcement, 25 September 2025 · Myopia Profile: US authorization and FIN-3101 figures · AAO: childhood myopia treatment options · AAPOS: treatment of increasing myopia in children · AAO Ophthalmic Technology Assessment: Ortho-K
This one is about a lens, not a frame
We sell kids' glasses. Stellest is clinical lens technology ordered and fitted through eye doctors — not a frame we can put in a cart. If your child's clinician recommends myopia-control spectacles, the win is wear time and the right optics. We will be here afterwards for frames, fit, backups and sports gear that survive real school days.
Shop kids' glasses